Read my last post in a series on data-related misconduct at startup Theranos outlined in the book, “Bad Blood”, where I discuss their lack of administrative barrier between research and clinical data.
Read my last post in a series on data-related misconduct at startup Theranos outlined in the book, “Bad Blood”, where I discuss their lack of administrative barrier between research and clinical data.
